As a result of the differences in the TfR distribution in normal and cancer cells, specific TfR-target strategies can be developed, not only for delivering therapeutic molecules to the brain tumor but also for serving as cancer biomarkers to correlate with tumor staging or cancer progression [51]. The gene discussed is TFRC; the disease is cancer.